Apollomics Enters $2 Million Unsecured Convertible Note with CEO
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen (Howard) Chen, aimed at providing working capital for clinical development programs and general operations, indicating an urgent need for liquidity within the company.
- Interest Rate and Conversion Terms: The note carries a 0% interest rate and will automatically convert into equity upon a future financing of at least $10 million, at a 20% discount to the lowest share price in that round, reflecting a flexible approach in the company's financing strategy to attract investors.
- Board Approval: The transaction has been approved by the company's audit committee and board, with Chen abstaining from the vote, highlighting the transparency of the company's governance structure in significant financial decisions.
- Market Reaction: Following the announcement, Apollomics' stock price fell 5.36% in pre-market trading to $15.0, indicating a cautious market sentiment regarding the company's financing method, which may impact future investor confidence.
Trade with 70% Backtested Accuracy
Analyst Views on APLM
About APLM
About the author
Apollomics Enters $2 Million Unsecured Convertible Note with CEO
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen (Howard) Chen, aimed at providing working capital for clinical development programs and general operations, indicating an urgent need for liquidity within the company.
- Interest Rate and Conversion Terms: The note carries a 0% interest rate and will automatically convert into equity upon a future financing of at least $10 million, at a 20% discount to the lowest share price in that round, reflecting a flexible approach in the company's financing strategy to attract investors.
- Board Approval: The transaction has been approved by the company's audit committee and board, with Chen abstaining from the vote, highlighting the transparency of the company's governance structure in significant financial decisions.
- Market Reaction: Following the announcement, Apollomics' stock price fell 5.36% in pre-market trading to $15.0, indicating a cautious market sentiment regarding the company's financing method, which may impact future investor confidence.
Apollomics Signs $2M Convertible Note with CEO for Clinical Development
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen Chen to provide short-term working capital for advancing clinical development programs and supporting general corporate operations.
- Interest Rate and Conversion Terms: Executed on March 30, 2026, the note carries a 0% interest rate and will automatically convert into Apollomics equity upon closing a future financing round of at least $10 million, with the conversion price set at a 20% discount to the lowest per-share price in the qualifying financing.
- Board Approval: The related-party transaction has been approved by the company's independent Audit Committee and Board, with Chen abstaining from the vote, reflecting the company's commitment to transparency and compliance in its financing decisions.
- Clinical Progress: Apollomics is advancing its lead program, Vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 multicohort trial for non-small cell lung cancer and other advanced tumors with c-Met alterations across the U.S. and more than 10 additional countries.
Apollomics Narrows H1 Loss to $12.56M Amid Revenue Growth
- Loss Narrowing: Apollomics reported a narrowed loss of $12.56 million for the first half, down from $35.21 million year-over-year, indicating improved financial management and boosting investor confidence.
- R&D Expense Reduction: Research and development expenses decreased significantly from $16.93 million to $4.62 million, reflecting effective cost control measures that could enhance future profitability.
- Revenue Growth: The company generated $8.5 million in revenue for the first half, compared to no revenue in the same period last year, demonstrating positive progress in market outreach and product development, potentially laying the groundwork for sustained growth.
- Strong Cash Position: Apollomics holds $2.1 million in cash and equivalents, which is expected to fund operations into Q3 2026, thereby strengthening its capacity for ongoing clinical trials and research investments.
Apollomics Reports 64% Reduction in Net Loss to $12.5 Million for H1 2025
- Financial Position Improvement: As of June 30, 2025, Apollomics reported cash and cash equivalents of $2.1 million, a significant decrease from $9.8 million as of December 31, 2024, indicating pressure on the company's liquidity management.
- Significant Reduction in R&D Expenses: R&D expenses for the first half of 2025 were $4.6 million, a 73% decrease from $16.9 million in the same period of 2024, reflecting a more cautious approach to research investments by the company.
- Increase in Administrative Expenses: General and administrative expenses rose to $14.5 million in the first half of 2025, up 42% from $10.2 million in the first half of 2024, highlighting cost pressures in operational management.
- Substantial Decrease in Loss Per Share: The net loss per share for the first half of 2025 was $11.37, down 70% from $37.53 in the same period of 2024, demonstrating significant progress in the company's efforts to control losses.
Apollomics Reveals Updates to Board of Directors and Committee Structure
Board Changes: Apollomics Inc. announced the resignation of Mr. Po-Jen Hsueh from its board, with Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy and join the Audit and Nominating Committees.
New Director's Background: Dr. Huang has extensive experience in biotechnology investment and corporate governance, currently serving as Assistant Vice President at Maxpro Ventures and previously as Investment Manager at Diamond Biofund.
Company Focus: Apollomics is a clinical-stage biopharmaceutical company specializing in oncology therapies, with its lead program, vebreltinib, currently in a Phase 2 clinical trial for non-small cell lung cancer.
Forward-Looking Statements: The press release includes forward-looking statements regarding Apollomics' strategies and anticipated outcomes, cautioning that these are subject to risks and uncertainties.
Lucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading
Lucas GC Limited Financial Results: Lucas GC Limited's shares surged 36.2% to $3.73 in pre-market trading after reporting H1 2025 earnings per share (EPS) of $1.47 on sales of $54.008 million.
Other Notable Gainers: MSP Recovery, Inc. saw a dramatic 262% increase to $0.7706, while SMX (Security Matters) Public Limited Company rose 72% to $3.47, among other significant pre-market gains.
Stocks Experiencing Losses: ZOOZ Strategy Ltd. dropped 28.3% to $1.01, and Alvotech fell 21.6% to $6.00, reflecting a trend of declines in several stocks after previous gains.
Market Overview: The pre-market trading session showed a mix of significant gains and losses across various stocks, indicating volatility in the market following recent trading activities.
Apollomics Enters $2 Million Unsecured Convertible Note with CEO
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen (Howard) Chen, aimed at providing working capital for clinical development programs and general operations, indicating an urgent need for liquidity within the company.
- Interest Rate and Conversion Terms: The note carries a 0% interest rate and will automatically convert into equity upon a future financing of at least $10 million, at a 20% discount to the lowest share price in that round, reflecting a flexible approach in the company's financing strategy to attract investors.
- Board Approval: The transaction has been approved by the company's audit committee and board, with Chen abstaining from the vote, highlighting the transparency of the company's governance structure in significant financial decisions.
- Market Reaction: Following the announcement, Apollomics' stock price fell 5.36% in pre-market trading to $15.0, indicating a cautious market sentiment regarding the company's financing method, which may impact future investor confidence.
Apollomics Signs $2M Convertible Note with CEO for Clinical Development
- Financing Arrangement: Apollomics has entered into a $2 million unsecured convertible promissory note with Chairman and CEO Hung-Wen Chen to provide short-term working capital for advancing clinical development programs and supporting general corporate operations.
- Interest Rate and Conversion Terms: Executed on March 30, 2026, the note carries a 0% interest rate and will automatically convert into Apollomics equity upon closing a future financing round of at least $10 million, with the conversion price set at a 20% discount to the lowest per-share price in the qualifying financing.
- Board Approval: The related-party transaction has been approved by the company's independent Audit Committee and Board, with Chen abstaining from the vote, reflecting the company's commitment to transparency and compliance in its financing decisions.
- Clinical Progress: Apollomics is advancing its lead program, Vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 multicohort trial for non-small cell lung cancer and other advanced tumors with c-Met alterations across the U.S. and more than 10 additional countries.
Apollomics Narrows H1 Loss to $12.56M Amid Revenue Growth
- Loss Narrowing: Apollomics reported a narrowed loss of $12.56 million for the first half, down from $35.21 million year-over-year, indicating improved financial management and boosting investor confidence.
- R&D Expense Reduction: Research and development expenses decreased significantly from $16.93 million to $4.62 million, reflecting effective cost control measures that could enhance future profitability.
- Revenue Growth: The company generated $8.5 million in revenue for the first half, compared to no revenue in the same period last year, demonstrating positive progress in market outreach and product development, potentially laying the groundwork for sustained growth.
- Strong Cash Position: Apollomics holds $2.1 million in cash and equivalents, which is expected to fund operations into Q3 2026, thereby strengthening its capacity for ongoing clinical trials and research investments.
Apollomics Reports 64% Reduction in Net Loss to $12.5 Million for H1 2025
- Financial Position Improvement: As of June 30, 2025, Apollomics reported cash and cash equivalents of $2.1 million, a significant decrease from $9.8 million as of December 31, 2024, indicating pressure on the company's liquidity management.
- Significant Reduction in R&D Expenses: R&D expenses for the first half of 2025 were $4.6 million, a 73% decrease from $16.9 million in the same period of 2024, reflecting a more cautious approach to research investments by the company.
- Increase in Administrative Expenses: General and administrative expenses rose to $14.5 million in the first half of 2025, up 42% from $10.2 million in the first half of 2024, highlighting cost pressures in operational management.
- Substantial Decrease in Loss Per Share: The net loss per share for the first half of 2025 was $11.37, down 70% from $37.53 in the same period of 2024, demonstrating significant progress in the company's efforts to control losses.
Apollomics Reveals Updates to Board of Directors and Committee Structure
Board Changes: Apollomics Inc. announced the resignation of Mr. Po-Jen Hsueh from its board, with Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy and join the Audit and Nominating Committees.
New Director's Background: Dr. Huang has extensive experience in biotechnology investment and corporate governance, currently serving as Assistant Vice President at Maxpro Ventures and previously as Investment Manager at Diamond Biofund.
Company Focus: Apollomics is a clinical-stage biopharmaceutical company specializing in oncology therapies, with its lead program, vebreltinib, currently in a Phase 2 clinical trial for non-small cell lung cancer.
Forward-Looking Statements: The press release includes forward-looking statements regarding Apollomics' strategies and anticipated outcomes, cautioning that these are subject to risks and uncertainties.
Lucas GC Shares Surge Over 36%; Check Out 20 Stocks Making Moves in Premarket Trading
Lucas GC Limited Financial Results: Lucas GC Limited's shares surged 36.2% to $3.73 in pre-market trading after reporting H1 2025 earnings per share (EPS) of $1.47 on sales of $54.008 million.
Other Notable Gainers: MSP Recovery, Inc. saw a dramatic 262% increase to $0.7706, while SMX (Security Matters) Public Limited Company rose 72% to $3.47, among other significant pre-market gains.
Stocks Experiencing Losses: ZOOZ Strategy Ltd. dropped 28.3% to $1.01, and Alvotech fell 21.6% to $6.00, reflecting a trend of declines in several stocks after previous gains.
Market Overview: The pre-market trading session showed a mix of significant gains and losses across various stocks, indicating volatility in the market following recent trading activities.
